

# Cosimo Bruni

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8528102/cosimo-bruni-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

|                    |                         |                |                 |
|--------------------|-------------------------|----------------|-----------------|
| 131<br>papers      | 1,445<br>citations      | 20<br>h-index  | 33<br>g-index   |
| 144<br>ext. papers | 2,063<br>ext. citations | 3.8<br>avg, IF | 4.72<br>L-index |

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 131 | Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2022</b> , 7, 24-32  | 2.3  | 5         |
| 130 | Lung involvement in systemic sclerosis. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2022</b> , 73-103   | 0.3  |           |
| 129 | Effectiveness of SB4 transition from originator etanercept in rheumatoid arthritis and axial spondyloarthritis: A subgroup analysis from the BENEFIT study. <i>Rheumatology and Immunology Research</i> , <b>2022</b> , 3, 31-37   | 0.2  |           |
| 128 | Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis-Interstitial Lung Disease: A Systematic Review.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 807982   | 4.9  | 0         |
| 127 | The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life. <i>Clinical Rheumatology</i> , <b>2021</b> , 1  | 3.9  | 2         |
| 126 | Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. <i>Diagnostics</i> , <b>2021</b> , 11,  | 3.8  | 4         |
| 125 | Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e834-e843        | 14.2 | 2         |
| 124 | Laser Speckle Contrast Analysis: Functional Evaluation of Microvascular Damage in Connective Tissue Diseases. Is There Evidence of Correlations With Organ Involvement, Such as Pulmonary Damage?. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 710298   | 4.6  | 3         |
| 123 | Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening. <i>Rheumatology</i> , <b>2021</b> ,  | 3.9  | 3         |
| 122 | Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102981  | 13.6 | 0         |
| 121 | Digital Ulcers. <i>In Clinical Practice</i> , <b>2021</b> , 111-122  | 0    |           |
| 120 | Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 653950   | 8.4  | 7         |
| 119 | Ultrasonographic imaging of systemic sclerosis digital ulcers: A systematic literature review and validation steps. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 425-429  | 5.3  | 1         |
| 118 | Digital Ulcers in Systemic Sclerosis. <i>Presse Medicale</i> , <b>2021</b> , 50, 104064  | 2.2  | 7         |
| 117 | The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients. <i>Pharmaceuticals</i> , <b>2021</b> , 14,  | 5.2  | 9         |
| 116 | POS0264 THE EMERGING ROLE OF MAGNETIC RESONANCE IMAGING IN INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: EVIDENCE FOR ULTRA SHORT TE AND COMPRESSED SENSING VIBE ACQUISITIONS AS PROMISING TOOLS FOR THE EVALUATION OF PARENCHYMAL ALTERATIONS. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 355.1-355 | 2.4  |           |
| 115 | POS1228 THE ROLE OF CHEST CT IN UNDERSTANDING INTERSTITIAL LUNG DISEASE (ILD): SYSTEMIC SCLEROSIS (SSc). VERSUS COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 897.2-898  | 2.4  |           |

|     |   |     |    |
|-----|---|-----|----|
| 114 | POS1495-HPR THE EXPERIENCE OF A RHEUMATOLOGY UNIT DURING THE COVID19 LOCKDOWN: TELEMEDICINE ALLOWS A SAFE FOLLOW UP OF PATIENTS WITH RHEUMATIC DISEASES. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1032.1-1032  | 2.4 |    |
| 113 | POS0321 USE OF HYDROXYCHLOROQUINE AND SYSTEMIC SCLEROSIS: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY ON THE EUSTAR COHORT. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 387.3-388  | 2.4 |    |
| 112 | POS0317 THE PERFORMANCE OF DIFFUSING CAPACITY FOR MONOXIDE CARBON (DLCO) AND FORCED VITAL CAPACITY (FVC) IN PREDICTING THE ONSET OF SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD) IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 385-386 | 2.4 |    |
| 111 | POS0861 EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 685-686   | 2.4 |    |
| 110 | Prediction and primary prevention of major vascular complications in systemic sclerosis. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 87, 51-58   | 3.9 | 2  |
| 109 | POS0855 PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 681.3-682  | 2.4 |    |
| 108 | Oral Species in Systemic Sclerosis. <i>Microorganisms</i> , <b>2021</b> , 9,  | 4.9 | 1  |
| 107 | Correlation between Potential Risk Factors and Pulmonary Embolism in Sarcoidosis Patients Timely Treated. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,   | 5.1 | 5  |
| 106 | The emerging challenge of pain in systemic sclerosis: Similarity to the pain experience reported by Sjögren's syndrome patients. <i>Rheumatology and Immunology Research</i> , <b>2021</b> , 2, 113-119   | 0.2 |    |
| 105 | The Renal Resistive Index: A New Biomarker for the Follow-up of Vascular Modifications in Systemic Sclerosis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 241-246  | 4.1 | 4  |
| 104 | Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 85-91  | 3.9 | 10 |
| 103 | Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 1903-1912   | 3.9 | 3  |
| 102 | Infection or Autoimmunity? The Clinical Challenge of Interstitial Lung Disease in Systemic Sclerosis During the COVID-19 Pandemic. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 790-792   | 4.1 | 2  |
| 101 | Patient preferences for systemic sclerosis treatment: A descriptive study within an Italian cohort.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2021</b> , 6, 165-169   | 2.3 | 0  |
| 100 | The role of ultrasound in systemic sclerosis: On the cutting edge to foster clinical and research advancement.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2021</b> , 6, 123-132  | 2.3 | 3  |
| 99  | COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2021</b> , 6, 58-65   | 2.3 | 6  |
| 98  | Response to: 'Correspondence on 'Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management'' by Snarskaya and Vasileva. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,  | 2.4 | 1  |
| 97  | Pulmonary arterial hypertension: guidelines and unmet clinical needs. <i>Reumatismo</i> , <b>2021</b> , 72, 228-246   | 1.1 | 5  |

|    |   |      |    |
|----|---|------|----|
| 96 | Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211014019                                | 3.8  | 1  |
| 95 | The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e149-e159   | 14.2 | 4  |
| 94 | Glycolysis-derived acidic microenvironment as a driver of endothelial dysfunction in systemic sclerosis. <i>Rheumatology</i> , <b>2021</b> , 60, 4508-4519  | 3.9  | 6  |
| 93 | The Treatment of Lung Involvement in Systemic Sclerosis. <i>Pharmaceuticals</i> , <b>2021</b> , 14,   | 5.2  | 7  |
| 92 | THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. <i>Rheumatology</i> , <b>2021</b> ,  | 3.9  | 15 |
| 91 | Cardiac involvement in systemic sclerosis: Getting to the heart of the matter. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2021</b> , 35, 101668  | 5.3  | 9  |
| 90 | Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211033679 | 3.8  | 1  |
| 89 | Systemic sclerosis and COVID-19: what's new in the literature. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 131, 157-158  | 2.2  | 1  |
| 88 | Prognostic Value of Lung Ultrasound B-Lines in Systemic Sclerosis. <i>Chest</i> , <b>2020</b> , 158, 1515-1525  | 5.3  | 22 |
| 87 | Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 724-726   | 2.4  | 38 |
| 86 | Further evidence that chilblains are a cutaneous manifestation of COVID-19 infection. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 596-598  | 4    | 7  |
| 85 | Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 78, 17-25   | 3.9  | 13 |
| 84 | Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,  | 5.1  | 2  |
| 83 | Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1210-1217  | 2.4  | 11 |
| 82 | Monitoring the microcirculation in the diagnosis and follow-up of systemic sclerosis patients: Focus on pulmonary and peripheral vascular manifestations. <i>Microcirculation</i> , <b>2020</b> , 27, e12647  | 2.9  | 13 |
| 81 | Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1489-1493   | 5.3  | 16 |
| 80 | Digital ulcers: should debridement be a standard of care in systemic sclerosis?. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e302-e307   | 14.2 | 4  |
| 79 | The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e71-e83  | 14.2 | 82 |

|    |   |     |    |
|----|---|-----|----|
| 78 | Digital ulcer debridement in systemic sclerosis: a systematic literature review. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 805-811   | 3.9 | 7  |
| 77 | Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study. <i>Rheumatology</i> , <b>2020</b> , 59, 580-585   | 3.9 | 4  |
| 76 | The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2020</b> , 12, 1759720X20964031 | 3.8 | 9  |
| 75 | The burning question: To use or not to use cyclophosphamide in systemic sclerosis. <i>European Journal of Rheumatology</i> , <b>2020</b> , 7, S237-S241   | 1.7 | 5  |
| 74 | The emerging role of lung ultrasound in COVID-19 pneumonia. <i>European Journal of Rheumatology</i> , <b>2020</b> , 7, S129-S133  | 1.7 | 14 |
| 73 | THU0355 PARAMETRIC CARDIAC MAGNETIC RESONANCE IMAGING IDENTIFIES ARRHYTHMOGENIC SUBSTRATES IN SYSTEMIC SCLEROSIS PATIENTS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 409.2-409  | 2.4 |    |
| 72 | OP0251 THE EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (SCLEROID) SCORE IS A NEW PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH SYSTEMIC SCLEROSIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 158-159                              | 2.4 |    |
| 71 | AB0281 SAFETY AND RETENTION RATE AFTER SWITCHING FROM ETANERCEPT ORIGINATOR (ETN) TO ETANERCEPT BIOSIMILAR (SB4) IN INFLAMMATORY JOINT DISEASES: DATA FROM REAL LIFE.. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1439.1-1440          | 2.4 |    |
| 70 | AB0556 PRIMARY SYSTEMIC SCLEROSIS HEART INVOLVEMENT (PSSCHI): A SYSTEMATIC LITERATURE REVIEW (SLR), CONSENSUS-BASED DEFINITION AND PRELIMINARY VALIDATION.. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1574.1-1575                     | 2.4 |    |
| 69 | AB0239 EFFECTS OF DYSMETABOLISMS AND COMORBIDITIES ON THE EFFICACY, SAFETY AND RETENTION RATE OF BIOLOGICAL DMARDS (bDMARD) IN INFLAMMATORY JOINT DISEASES.. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1420.1-1420                    | 2.4 |    |
| 68 | SAT0308 SCREENING TOOLS FOR PULMONARY ARTERIAL HYPERTENSION (PAH) IN SYSTEMIC SCLEROSIS (SSC): A SYSTEMATIC LITERATURE REVIEW (SLR).. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1099.1-1099   | 2.4 |    |
| 67 | THU0360 EFFICACY OF A SELF-TREATMENT PROTOCOL FOR FACE AND TEMPOROMANDIBULAR JOINTS REHABILITATION IN SYSTEMIC SCLEROSIS (SSC). <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 411.2-411   | 2.4 |    |
| 66 | AB0361 EFFICACY AND SAFETY OF BARICITINIB (BARI) IN RHEUMATOID ARTHRITIS(RA): CLINICAL AND ULTRASOUND EVALUATION IN REAL LIFE. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1481-1482  | 2.4 |    |
| 65 | Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience. <i>Rheumatology and Immunology Research</i> , <b>2020</b> , 1, 39-45  | 0.2 |    |
| 64 | Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). <i>Rheumatology</i> , <b>2020</b> , 59, 1938-1948  | 3.9 | 16 |
| 63 | Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. <i>Rheumatology</i> , <b>2020</b> , 59, 3731-3736   | 3.9 | 10 |
| 62 | What Role Does Trabecular Bone Score Play in Chronic Inflammatory Rheumatic Diseases?. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 600697   | 4.9 | 5  |
| 61 | The need for a holistic approach for SSs-ILD - achievements and ambiguity in a devastating disease. <i>Respiratory Research</i> , <b>2020</b> , 21, 197   | 7.3 | 13 |

|    |  |     |    |
|----|--|-----|----|
| 60 | Pleuroparenchymal fibroelastosis in rheumatic autoimmune diseases: a systematic literature review. <i>Rheumatology</i> , <b>2020</b> , 59, 3645-3656   | 3.9 | 3  |
| 59 | Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 27-36 | 3.9 | 11 |
| 58 | Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 881-887   | 4.1 | 16 |
| 57 | Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 125, 161-168       | 2.2 | 3  |
| 56 | The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 70, 43-49  | 3.9 | 3  |
| 55 | Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. <i>Clinical and Experimental Medicine</i> , <b>2019</b> , 19, 357-366                                    | 4.9 | 15 |
| 54 | Cyclophosphamide: similarities and differences in the treatment of SSc and SLE. <i>Lupus</i> , <b>2019</b> , 28, 571-574   | 4.6 | 4  |
| 53 | Near-infrared spectroscopic imaging of the whole hand: A new tool to assess tissue perfusion and peripheral microcirculation in scleroderma. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 867-873   | 5.3 | 8  |
| 52 | Hand Function in Scleroderma <b>2019</b> , 91-107  |     |    |
| 51 | Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?. <i>Medicine (United States)</i> , <b>2019</b> , 98, e16086  | 1.8 | 3  |
| 50 | Early Detection of Cardiac Involvement in Systemic Sclerosis: The Added Value of Magnetic Resonance Imaging. <i>JACC: Cardiovascular Imaging</i> , <b>2019</b> , 12, 927-928   | 8.4 | 12 |
| 49 | Ulcer Healing and Prevention in Systemic Sclerosis <b>2019</b> , 167-171   |     | 1  |
| 48 | Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 603-608  | 4.1 | 12 |
| 47 | Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 78-84                          | 4.1 | 7  |
| 46 | 18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 577-578   | 2.4 | 12 |
| 45 | Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 575-577  | 2.4 | 3  |
| 44 | The safety of iloprost in systemic sclerosis in a real-life experience. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 1249-1255   | 3.9 | 10 |
| 43 | Kidney involvement in systemic sclerosis: From pathogenesis to treatment.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2018</b> , 3, 43-52  | 2.3 | 22 |



|    |   |     |    |
|----|---|-----|----|
| 42 | Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000782  | 5.9 | 53 |
| 41 | L'hydroxychloroquine et les atteintes articulaires dans la sclérodémie systémique: résultats préliminaires d'une étude rétrospective cas-témoins EUSTAR. <i>Revue Du Rhumatisme (Edition Française)</i> , <b>2018</b> , 85, 411-412 | 0.1 |    |
| 40 | Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2045  | 8.4 | 36 |
| 39 | The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interaction. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 113, 135-141                | 2.2 | 2  |
| 38 | Proangiogenic effects of soluble Klotho on systemic sclerosis dermal microvascular endothelial cells. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 27  | 5.7 | 19 |
| 37 | Use of biologics and other novel therapies for the treatment of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 469-482   | 5.1 | 24 |
| 36 | Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1190-1197  | 4.1 | 13 |
| 35 | Avascular bone necrosis: An underestimated complication of systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 47, e3-e5  | 5.3 | 5  |
| 34 | Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. <i>Joint Bone Spine</i> , <b>2017</b> , 84, 747-748                    | 2.9 | 12 |
| 33 | Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition. <i>Journal of Scleroderma and Related Disorders</i> , <b>2017</b> , 2, 115-120                 | 2.3 | 49 |
| 32 | Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour. <i>Rheumatology</i> , <b>2017</b> , 56, 317-318  | 3.9 | 12 |
| 31 | Lidocaine controls pain and allows safe wound bed preparation and debridement of digital ulcers in systemic sclerosis: a retrospective study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 209-212                              | 3.9 | 12 |
| 30 | One year in review 2017: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 106, 3-20   | 2.2 | 9  |
| 29 | One year in review 2017: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 875-884  | 2.2 | 3  |
| 28 | OP0050 Serum Levels of Adipokines in The Categories of Body Mass Index (BMI) in Patients with Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 73.2-73   | 2.4 |    |
| 27 | Calcinosis in systemic sclerosis: subsets, distribution and complications. <i>Rheumatology</i> , <b>2016</b> , 55, 1610-4   | 3.9 | 23 |
| 26 | Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 127-32                 | 3.9 | 20 |
| 25 | Critical finger ischemia and myocardial fibrosis development after sudden interruption of sildenafil treatment in a systemic sclerosis patient. <i>Reumatismo</i> , <b>2016</b> , 68, 109-11  | 1.1 | 3  |

|    |   |     |     |
|----|---|-----|-----|
| 24 | SAT0229 A Novel Serum Test Based Algorithm To Aid in Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 751.2-751   | 2.4 |     |
| 23 | Premedication prevents infusion reactions and improves retention rate during infliximab treatment. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 2841-2845   | 3.9 | 15  |
| 22 | One year in review 2016: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 161-71   | 2.2 | 20  |
| 21 | The clinical relevance of sexual dysfunction in systemic sclerosis. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 1111-53.6   | 3.6 | 13  |
| 20 | Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 795-8  | 3.9 | 8   |
| 19 | Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. <i>Rheumatology</i> , <b>2015</b> , 54, 72-6   | 3.9 | 43  |
| 18 | Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 124-8  | 2.4 | 43  |
| 17 | Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 221  | 5.7 | 23  |
| 16 | AB0726 Combination Therapy with Bosentan and Sildenafil Improves Nailfold Videocapillaroscopy in Systemic Sclerosis (SSC). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1141.1-1141  | 2.4 |     |
| 15 | A6.28 The role of Plexin-D1/Semaphorin 3E pathway in the dysregulation of vascular tone control in systemic sclerosis (SSc). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, A67.1-A67  | 2.4 |     |
| 14 | Antioxidant agents help primary Raynaud's phenomenon. <i>International Angiology</i> , <b>2015</b> , 34, 94-5   | 2.2 |     |
| 13 | Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S148-52   | 2.2 | 6   |
| 12 | One year in review 2015: systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, 414-25   | 2.2 | 20  |
| 11 | Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 2087-93 | 2.4 | 121 |
| 10 | AB0643 The EReuma Project: Role of Early and Recent Life Events on Systemic Sclerosis (SSC) Clinical Presentation and Course. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1018.1-1018   | 2.4 |     |
| 9  | Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 390-5  | 2.4 | 109 |
| 8  | Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 319-21  | 2.4 | 30  |
| 7  | Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1425-7  | 2.4 | 30  |



|   |  |     |                |
|---|--|-----|----------------|
| 6 | SAT0150 Soluble FAS/FASL levels in rheumatoid arthritis patients treated with infliximab and adalimumab. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 522.2-522   | 2.4 |                |
| 5 | SAT0034 Cardiac involvement in systemic sclerosis: The added value of magnetic resonance imaging. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 482.2-482  | 2.4 |                |
| 4 | AB0466 Quantiferon (QFT) identifies latent tuberculosis (LTB) but does not help the evaluation of the efficacy of prophylaxis in inflammatory arthritides. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 664.6-664 | 2.4 |                |
| 3 | AB0230 Anorectal involvement in very early systemic sclerosis (SSC). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 650.13-650  | 2.4 |                |
| 2 | AB0231 Esophageal involvement in very early systemic sclerosis (SSC). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 650.14-650   | 2.4 |                |
| 1 | Bosentan fosters microvascular de-remodelling in systemic sclerosis. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 1723-5   | 3.9 | 4 <sup>8</sup> |